Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.

Dankner M, Ouellet V, Communal L, Schmitt E, Perkins D, Annis MG, Barrès V, Caron C, Mes-Masson AM, Saad F, Siegel PM; Canadian Prostate Cancer Biomarker Network.

Am J Pathol. 2019 Jun 11. pii: S0002-9440(18)31099-X. doi: 10.1016/j.ajpath.2019.04.006. [Epub ahead of print]

PMID:
31202437
2.

Canadian Tissue Repository Network Biobank Certification Program: Update and Review of the Program from 2011 to 2018.

Hartman V, Gali B, Dee S, O'Donoghue S, Tarling T, Barnes R, de Ladurantaye M, Mes-Masson AM, Watson PH.

Biopreserv Biobank. 2019 Jun 13. doi: 10.1089/bio.2019.0015. [Epub ahead of print]

PMID:
31194579
3.

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.

Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier MA, Sauriol A, Communal L, Leclerc-Desaulniers K, Carmona E, Provencher D, Mes-Masson AM, Rodier F.

Nat Commun. 2019 Jun 11;10(1):2556. doi: 10.1038/s41467-019-10460-1.

PMID:
31186408
4.

Long-term fluorescence hyperspectral imaging of on-chip treated co-culture tumour spheroids to follow clonal evolution.

St-Georges-Robillard A, Cahuzac M, Péant B, Fleury H, Lateef MA, Ricard A, Sauriol A, Leblond F, Mes-Masson AM, Gervais T.

Integr Biol (Camb). 2019 Jun 7. pii: zyz012. doi: 10.1093/intbio/zyz012. [Epub ahead of print]

PMID:
31172192
5.

Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.

Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, Dionne N, Delouya G, Kougioumoutzakis A, Sirois J, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Zorn KC, Fradet Y, Saad F, Taussky D, Trudel D.

Radiat Oncol. 2019 Apr 25;14(1):60. doi: 10.1186/s13014-019-1267-3.

6.

A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma.

Le Page C, Köbel M, Meunier L, Provencher DM, Mes-Masson AM, Rahimi K.

J Pathol Clin Res. 2019 Mar 28. doi: 10.1002/cjp2.131. [Epub ahead of print]

7.

Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification.

Monette A, Bergeron D, Ben Amor A, Meunier L, Caron C, Mes-Masson AM, Kchir N, Hamzaoui K, Jurisica I, Lapointe R.

J Immunother Cancer. 2019 Mar 28;7(1):86. doi: 10.1186/s40425-019-0544-x.

8.

Distinct Histologic, Immunohistochemical and Clinical Features Associated With Serous Endometrial Intraepithelial Carcinoma Involving Polyps.

Trinh VQ, Pelletier MP, Echelard P, Warkus T, Sauthier P, Gougeon F, Mès-Masson AM, Provencher DM, Rahimi K.

Int J Gynecol Pathol. 2019 Feb 14. doi: 10.1097/PGP.0000000000000591. [Epub ahead of print]

PMID:
30789501
9.

Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumors.

Simeone K, Guay-Lord R, Lateef MA, Péant B, Kendall-Dupont J, Orimoto AM, Carmona E, Provencher D, Saad F, Gervais T, Mes-Masson AM.

Lab Chip. 2019 Feb 12;19(4):693-705. doi: 10.1039/c8lc00982a.

PMID:
30671574
10.

Prognostic value of progesterone receptor expression in tubo-ovarian high-grade serous carcinoma of the COEUR cohort.

Le Page C, Rahimi K, Mes-Masson AM, Köbel M.

Histopathology. 2019 Mar;74(4):663-666. doi: 10.1111/his.13784. Epub 2019 Jan 15. No abstract available.

PMID:
30403298
11.

Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer.

Sharma NV, Pellegrini KL, Ouellet V, Giuste FO, Ramalingam S, Watanabe K, Adam-Granger E, Fossouo L, You S, Freeman MR, Vertino P, Conneely K, Osunkoya AO, Trudel D, Mes-Masson AM, Petros JA, Saad F, Moreno CS.

Cancers (Basel). 2018 Oct 11;10(10). pii: E379. doi: 10.3390/cancers10100379.

12.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

13.

Replication Protein A Availability during DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells.

Bélanger F, Fortier E, Dubé M, Lemay JF, Buisson R, Masson JY, Elsherbiny A, Costantino S, Carmona E, Mes-Masson AM, Wurtele H, Drobetsky E.

Cancer Res. 2018 Oct 1;78(19):5561-5573. doi: 10.1158/0008-5472.CAN-18-0618. Epub 2018 Aug 2.

PMID:
30072396
14.

Fluorescence hyperspectral imaging for live monitoring of multiple spheroids in microfluidic chips.

St-Georges-Robillard A, Masse M, Cahuzac M, Strupler M, Patra B, Orimoto AM, Kendall-Dupont J, Péant B, Mes-Masson AM, Leblond F, Gervais T.

Analyst. 2018 Aug 6;143(16):3829-3840. doi: 10.1039/c8an00536b.

PMID:
29999046
15.

The Canadian Partnership for Tomorrow Project: a pan-Canadian platform for research on chronic disease prevention.

Dummer TJB, Awadalla P, Boileau C, Craig C, Fortier I, Goel V, Hicks JMT, Jacquemont S, Knoppers BM, Le N, McDonald T, McLaughlin J, Mes-Masson AM, Nuyt AM, Palmer LJ, Parker L, Purdue M, Robson PJ, Spinelli JJ, Thompson D, Vena J, Zawati M; with the CPTP Regional Cohort Consortium.

CMAJ. 2018 Jun 11;190(23):E710-E717. doi: 10.1503/cmaj.170292.

16.

Describing perspectives of health care professionals on active surveillance for the management of prostate cancer.

Pang K, Fitch M, Ouellet V, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, So A, Sutcliffe S, Tanguay S, Saad F, Mes-Masson AM.

BMC Health Serv Res. 2018 Jun 8;18(1):430. doi: 10.1186/s12913-018-3273-9.

17.

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.

Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI.

Pathol Oncol Res. 2018 Apr 6. doi: 10.1007/s12253-018-0408-6. [Epub ahead of print]

PMID:
29623528
18.

The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival.

Trinh VQ, Sirois J, Benzerdjeb N, Mansoori BK, Grosset AA, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Ladouceur M, Fradet Y, Saad F, Trudel D.

Prostate. 2018 Jul;78(10):697-706. doi: 10.1002/pros.23513. Epub 2018 Mar 30.

PMID:
29603326
19.

Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.

Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.

BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.

20.

Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.

Annis MG, Ouellet V, Rennhack JP, L'Esperance S, Rancourt C, Mes-Masson AM, Andrechek ER, Siegel PM.

Breast Cancer Res. 2018 Jan 30;20(1):9. doi: 10.1186/s13058-018-0936-8.

21.

Multi-size spheroid formation using microfluidic funnels.

Marimuthu M, Rousset N, St-Georges-Robillard A, Lateef MA, Ferland M, Mes-Masson AM, Gervais T.

Lab Chip. 2018 Jan 16;18(2):304-314. doi: 10.1039/c7lc00970d.

PMID:
29211088
22.

Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources.

Fitch M, Pang K, Ouellet V, Loiselle C, Alibhai S, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, Sutcliffe S, So A, Tanguay S, Saad F, Mes-Masson AM.

BMC Urol. 2017 Oct 27;17(1):98. doi: 10.1186/s12894-017-0290-7.

23.

Dimension reduction technique using a multilayered descriptor for high-precision classification of ovarian cancer tissue using optical coherence tomography: a feasibility study.

St-Pierre C, Madore WJ, De Montigny E, Trudel D, Boudoux C, Godbout N, Mes-Masson AM, Rahimi K, Leblond F.

J Med Imaging (Bellingham). 2017 Oct;4(4):041306. doi: 10.1117/1.JMI.4.4.041306. Epub 2017 Oct 12.

24.

Engineered in-vitro cell line mixtures and robust evaluation of computational methods for clonal decomposition and longitudinal dynamics in cancer.

Farahani H, de Souza CPE, Billings R, Yap D, Shumansky K, Wan A, Lai D, Mes-Masson AM, Aparicio S, P Shah S.

Sci Rep. 2017 Oct 18;7(1):13467. doi: 10.1038/s41598-017-13338-8.

25.

Tissue and plasma levels of galectins in patients with high grade serous ovarian carcinoma as new predictive biomarkers.

Labrie M, De Araujo LOF, Communal L, Mes-Masson AM, St-Pierre Y.

Sci Rep. 2017 Oct 16;7(1):13244. doi: 10.1038/s41598-017-13802-5.

26.

Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.

Corkery DP, Clarke LE, Gebremeskel S, Salsman J, Pinder J, Le Page C, Meunier L, Xu Z, Mes-Masson AM, Berman JN, Johnston B, Dellaire G.

Oncogene. 2018 Jan 11;37(2):174-184. doi: 10.1038/onc.2017.318. Epub 2017 Sep 11.

27.

Morphologic three-dimensional scanning of fallopian tubes to assist ovarian cancer diagnosis.

Madore WJ, De Montigny E, Deschênes A, Benboujja F, Leduc M, Mes-Masson AM, Provencher DM, Rahimi K, Boudoux C, Godbout N.

J Biomed Opt. 2017 Jul 1;22(7):76012. doi: 10.1117/1.JBO.22.7.076012.

PMID:
28727868
28.

Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma.

Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, Burk DL, Grapton D, Tomiak E, Hastings V, Hamel N, Wagener R, Aleynikova O, Giroux S, Hamdan FF, Dionne-Laporte A, Zogopoulos G, Rousseau F, Berghuis AM, Provencher D, Rouleau GA, Michaud JL, Mes-Masson AM, Majewski J, Bens S, Siebert R, Narod SA, Akbari MR, Lord CJ, Tonin PN, Orthwein A, Foulkes WD.

Cancer Res. 2017 Aug 15;77(16):4517-4529. doi: 10.1158/0008-5472.CAN-17-0190. Epub 2017 Jun 23.

29.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP.

Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24.

PMID:
28436987
30.

The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.

He Y, Northey JJ, Pelletier A, Kos Z, Meunier L, Haibe-Kains B, Mes-Masson AM, Côté JF, Siegel PM, Lamarche-Vane N.

Oncogene. 2017 Jun 15;36(24):3490-3503. doi: 10.1038/onc.2016.492. Epub 2017 Jan 30.

31.

Hormonal and reproductive factors and the risk of ovarian cancer.

Koushik A, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, Gotlieb WH, Lacaille J, Mes-Masson AM, Parent MÉ, Provencher DM, Richardson L, Siemiatycki J.

Cancer Causes Control. 2017 May;28(5):393-403. doi: 10.1007/s10552-016-0848-9. Epub 2017 Jan 19.

PMID:
28102526
32.

Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction.

Couturier AM, Fleury H, Patenaude AM, Bentley VL, Rodrigue A, Coulombe Y, Niraj J, Pauty J, Berman JN, Dellaire G, Di Noia JM, Mes-Masson AM, Masson JY.

Nucleic Acids Res. 2016 Dec 15;44(22):10879-10897. Epub 2016 Oct 24.

33.

STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer.

Au KK, Le Page C, Ren R, Meunier L, Clément I, Tyrishkin K, Peterson N, Kendall-Dupont J, Childs T, Francis JA, Graham CH, Craig AW, Squire JA, Mes-Masson AM, Koti M.

J Pathol Clin Res. 2016 Sep 19;2(4):259-270. eCollection 2016 Oct.

34.

Microcystic, elongated, and fragmented pattern invasion is mainly associated with isolated tumor cell pattern metastases in International Federation of Gynecology and Obstetrics grade I endometrioid endometrial cancer.

Pelletier MP, Trinh VQ, Stephenson P, Mes-Masson AM, Samouelian V, Provencher DM, Rahimi K.

Hum Pathol. 2017 Apr;62:33-39. doi: 10.1016/j.humpath.2016.10.023. Epub 2016 Nov 15.

PMID:
27864117
35.

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.

Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, Rosenfeld N, Mes Masson AM, Brenton JD.

J Pathol Clin Res. 2016 Jul 13;2(4):247-258. eCollection 2016 Oct.

36.

Biopsy Based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy.

Saad F, Latour M, Lattouf JB, Widmer H, Zorn KC, Mes-Masson AM, Ouellet V, Saad G, Prakash A, Choudhury S, Han G, Karakiewicz P, Richie JP.

J Urol. 2017 Apr;197(4):1034-1040. doi: 10.1016/j.juro.2016.09.116. Epub 2016 Oct 8.

PMID:
27725152
37.

IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression.

Péant B, Gilbert S, Le Page C, Poisson A, L'Ecuyer E, Boudhraa Z, Bienz MN, Delvoye N, Saad F, Mes-Masson AM.

Oncotarget. 2017 Feb 28;8(9):14487-14501. doi: 10.18632/oncotarget.11629.

38.

Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study.

Timilshina N, Ouellet V, Alibhai SM, Mes-Masson AM, Delvoye N, Drachenberg D, Finelli A, Jammal MP, Karakiewicz P, Lapointe H, Lattouf JB, Lynch K, Paradis JB, Sitarik P, So A, Saad F.

World J Urol. 2017 Apr;35(4):595-603. doi: 10.1007/s00345-016-1897-0. Epub 2016 Jul 22.

PMID:
27447989
39.

Robust high-performance nanoliter-volume single-cell multiple displacement amplification on planar substrates.

Leung K, Klaus A, Lin BK, Laks E, Biele J, Lai D, Bashashati A, Huang YF, Aniba R, Moksa M, Steif A, Mes-Masson AM, Hirst M, Shah SP, Aparicio S, Hansen CL.

Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):8484-9. doi: 10.1073/pnas.1520964113. Epub 2016 Jul 13.

40.

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.

Fleury H, Carmona E, Morin VG, Meunier L, Masson JY, Tonin PN, Provencher D, Mes-Masson AM.

Oncotarget. 2017 Jun 20;8(25):40152-40168. doi: 10.18632/oncotarget.10308.

41.

An Immunohistochemical Algorithm for Ovarian Carcinoma Typing.

Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, de Ladurantaye M, Lee S, Leung S, Goode EL, Ramus SJ, Carlson JW, Li X, Ewanowich CA, Kelemen LE, Vanderhyden B, Provencher D, Huntsman D, Lee CH, Gilks CB, Mes Masson AM.

Int J Gynecol Pathol. 2016 Sep;35(5):430-41. doi: 10.1097/PGP.0000000000000274.

42.

The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin.

Andreev E, Brosseau N, Carmona E, Mes-Masson AM, Ramotar D.

Sci Rep. 2016 Feb 10;6:20508. doi: 10.1038/srep20508.

43.

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

Koti M, Siu A, Clément I, Bidarimath M, Turashvili G, Edwards A, Rahimi K, Mes-Masson AM, Squire JA.

Br J Cancer. 2015 Dec 22;113(12):1746. doi: 10.1038/bjc.2015.459. No abstract available.

44.

Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy.

Astolfi M, Péant B, Lateef MA, Rousset N, Kendall-Dupont J, Carmona E, Monet F, Saad F, Provencher D, Mes-Masson AM, Gervais T.

Lab Chip. 2016 Jan 21;16(2):312-25. doi: 10.1039/c5lc01108f.

PMID:
26659477
45.

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease.

Fleury H, Communal L, Carmona E, Portelance L, Arcand SL, Rahimi K, Tonin PN, Provencher D, Mes-Masson AM.

Genes Cancer. 2015 Sep;6(9-10):378-398.

46.

Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience.

Lee S, Piskorz AM, Le Page C, Mes Masson AM, Provencher D, Huntsman D, Chen W, Swanson PE, Gilks CB, Köbel M.

Int J Gynecol Pathol. 2016 May;35(3):209-21. doi: 10.1097/PGP.0000000000000251.

PMID:
26598982
47.

Expression of Stem Cell Markers in Preinvasive Tubal Lesions of Ovarian Carcinoma.

Chene G, Ouellet V, Rahimi K, Barres V, Meunier L, De Ladurantaye M, Provencher D, Mes-Masson AM.

Biomed Res Int. 2015;2015:808531. doi: 10.1155/2015/808531. Epub 2015 Oct 4.

48.

CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DM, Haibe-Kains B, Karn T, Rahimi K, Le Page C, Provencher D, Mes-Masson AM, Stagg J.

Cancer Res. 2015 Nov 1;75(21):4494-503. doi: 10.1158/0008-5472.CAN-14-3569. Epub 2015 Sep 11.

49.

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.

Marques M, Beauchamp MC, Fleury H, Laskov I, Qiang S, Pelmus M, Provencher D, Mes-Masson AM, Gotlieb WH, Witcher M.

BMC Med. 2015 Sep 9;13:217. doi: 10.1186/s12916-015-0454-9.

50.

Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay.

Labouba I, Le Page C, Communal L, Kristessen T, You X, Péant B, Barrès V, Gannon PO, Mes-Masson AM, Saad F.

PLoS One. 2015 Jul 17;10(7):e0131024. doi: 10.1371/journal.pone.0131024. eCollection 2015.

Supplemental Content

Loading ...
Support Center